Metastatic Breast Cancer

Watch Dr. Leif Ellisen, Dr. Dejan Juric, Dr. Beverly Moy and Natasha Mmeje answer questions about unmet needs during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Beverly Moy, from Massachusetts General Hospital, discuss addressing breast cancer disparity during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Dejan Juric, from Massachusetts General Hospital, discuss therapeutic resistance during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Aditya Bardia, Dr. Arielle J. Medford and Dr. Neelima Vidula answer questions about HER2 and triple-negative disease during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Neelima Vidula, from Massachusetts General Hospital, discuss the management of triple-negative disease during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Arielle J. Medford, from Dana-Farber Cancer Institute, discuss the management of HER2-positive disease during the CURE® Educated Patient® Metastatic Breast Cancer Summit.

Watch Dr. Aditya Bardia, Dr. Seth A. Wander and Dr. Laura M. Spring answer questions about HR-positive disease during the CURE Educated Patient Metastatic Breast Cancer Summit.

Watch Dr. Laura M. Spring, from Massachusetts General Hospital in Boston, discuss treatment in third line and beyond for hormone receptor-positive breast cancer, during the CURE® Educated Patient® Metastatic Breast Cancer Summit.

Watch Dr. Seth A. Wander, from Massachusetts General Hospital in Boston, discuss the first- and second-line treatment of hormone receptor-positive breast cancer, during the CURE® Educated Patient® Metastatic Breast Cancer Summit.

When patients are aware of cancer disparities, it can empower them to be proactive about their care to close the prognostic gap between races.

I had a wonderful time at a recent breast cancer walk, until I got home and found a bracelet with a raunchy saying on it in my survivor’s gift bag.

With a little luck and a lot of coordination, I managed to create an excellent and comprehensive cancer care team in the least populated state in the country.

Since I have stage 4 breast cancer, I wanted an oncologist affiliated with a research institution. However, I hated the prospect of frequent long drives for care. Luckily, I got the best of both worlds.

When people say. “It’s just $35 to see a specialist,” they miss the entire issue of cancer-related financial toxicity.

The Food and Drug Administration granted a priority review to Trodelvy for previously treated locally advanced or metastatic HR-positive, HER2-negative breast cancer.

I wish “Pinktober” was more about saving the people who will die from breast cancer and less about pink ribbons and sexualizing the disease.

From the death of standup comedian and "Love Goddess" Judy Tenuta to professional sports hall-of-famers discussing their cancer, here’s what’s happening in the cancer space this week.

A patient with metastatic breast cancer shares how she learned that her disease was recently reclassified as HER-2 low, and what it was like to first learn about the FDA-approved drug years before she would be prescribed the treatment.

On the same day that I learned of my cancer progression, I also found out I had COVID-19. Here’s how I handled that dark period of life.

Extra years with my family meant missing out on a free trip granted to patients with cancer who have children under the age of 18 — and I’m OK with that.

As “Pinktober” approaches, I’m spreading the message that breasts are not needed to live a full life after breast cancer surgery.

Compared to physician’s choice of treatment, Trodelvy improved survival and quality of life in pretreated patients with HR positive/HER2 negative metastatic breast cancer.

I’ve channeled my cancer-related anger into advocacy, and made a “living list” of things I want to accomplish.

Trodelvy bested chemotherapy for progression-free survival in patients with HR-positive, HER2-negative metastatic breast cancer.

I’m giving cancer’s “battle language” an update and focusing my survivorship plan on emotional wellbeing and honesty.